Shreveport, LA

Omni Fertility and Laser Institute

Leiomyoma

Endometriosis

Myofibroma

Herpes Genitalis

Herpes Simplex

Vilaprisan

MT-2990

OG-6219

Famciclovir

Bayer

Mitsubishi Tanabe Pharma

Novartis

Organon

condition

allSponsorName

IQVIA

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared with Placebo in Participants Aged 18 to 49 with Moderate to Severe Endometriosis-related Pain

Omni Fertility and Laser Institute | Shreveport, LA

Site insights

Work at this site?

Active trials

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared with Placebo in Participants Aged 18 to 49 with Moderate to Severe Endometriosis-related Pain (ELENA)

Trial sponsors